PTGX Q4 2018 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-79.1% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$15M-655.0% margin

Net Income

-$14M-589.2% margin

EPS (Diluted)

$-0.57

QoQ Revenue Growth

-61.5%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$139M

Total Liabilities

$27M

Stockholders' Equity

-$140M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$11M	-79.1%
Gross Profit	$2M	$11M	-79.1%
Operating Income	-$15M	-$4M	-338.7%
Net Income	-$14M	-$3M	-354.3%